Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs

References

• MohammadHPBaylinSBLinking cell signaling and the epigenetic machineryNat Biotechnol2010281033103820944593
   PubMed Web of Science ®Google Scholar
• Portela1AEstellerMEpigenetic modifications and human diseaseNat Biotechnol2010281057106820944598
   PubMed Web of Science ®Google Scholar
• KellyTKDe CarvalhoDDJonesPAEpigenetic modifications as therapeutic targetsNat Biotechnol2010281069107820944599
   PubMed Web of Science ®Google Scholar
• FalkenbergKJJohnstoneRWHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disordersNat Rev Drug Discov20141367369125131830
   PubMed Web of Science ®Google Scholar
• WestACJohnstoneRWNew and emerging HDAC inhibitors for cancer treatmentJ Clin Invest20141213039
   Web of Science ®Google Scholar
• MottamalMZhengSHuangTLWangGHistone deacetylase inhibitors in clinical studies as templates for new anticancer agentsMolecules2015203898394125738536
   PubMed Web of Science ®Google Scholar
• GuhaMHDAC inhibitors still need a home run, despite recent approvalNat Rev Drug Discov20151422522625829268
   PubMed Web of Science ®Google Scholar
• MicelliCRastelliGHistone deacetylases: structural determinants of inhibitor selectivityDrug Discov Today201520671873525687212
   PubMed Web of Science ®Google Scholar
• De RuijterAJMVan GennipAHCaronHNKempSVan KuilenburgABPHistone deacetylases (HDACs): characterization of the classical HDAC familyBiochem J200337073774912429021
   PubMed Web of Science ®Google Scholar
• HoutkooperRHPirinenEAuwerxJSirtuins as regulators of metabolism and healthspanNat Rev Mol Cell Biol20121322523822395773
   PubMed Web of Science ®Google Scholar
• ZhaoRMasayasuHHolmgrenAEbselen: a substrate for human thioredoxin reductaseProc Natl Acad Sci U S A200299138579858412070343
   PubMed Web of Science ®Google Scholar
• ScheweCScheweTWendelAStrong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathioneBiochem Pharmacol199448165748043032
   PubMed Web of Science ®Google Scholar
• SmithSMMinJGaneshTDieboldBEbselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunitsChem Biol201219675276322726689
   PubMedGoogle Scholar
• BeilWStaarUSewingKFInteraction of the anti-inflammatory seleno-organic compound ebselen with acid secretion in isolated parietal cells and gastric H+/K+-ATPaseBiochem Pharmacol1990409199720032173597
   PubMed Web of Science ®Google Scholar
• ZembowiczAHatchettRJRadziszewskiWGryglewskiRJInhibition of endothelial nitric oxide synthase by ebselenJ Pharmacol Exp Ther19932673111211187505326
   PubMed Web of Science ®Google Scholar
• SinghNHallidayACThomasJMA safe lithium mimetic for bipolar disorderNat Commun20134133223299882
   PubMed Web of Science ®Google Scholar
• ParnhamMSiesHEbselen: prospective therapy for cerebral ischaemiaExpert Opin Investig Drugs200093607619
   PubMed Web of Science ®Google Scholar
• Enzo. SCREEN-WELL FDA approved drug library V2Accelerates drug optimization with a unique collection of compounds of known safety and bioavailability for diverse targets Available from: http://www.enzolifesciences.com/BML-2843/screen-well-fda-approved-drug-library-v2/Accessed March 27, 2017
   Google Scholar
• National Institutes of Health (NIH) Clinical Collection library Available from: www.nihclinicalcollection.comAccessed March 27, 2017
   Google Scholar
• WegenerDWirschingFRiesterDSchwienhorstAA fluorogenic histone deacetylase assay well suited for high-throughput activity screeningChem Biol200310616812573699
   PubMed Web of Science ®Google Scholar
• LiYShinHKwonSHHistone deacetylase 6 plays a role as a distinct regulator of diverse cellular processesFEBS J201328077579323181831
   PubMed Web of Science ®Google Scholar
• SantoLHideshimaTKungALPreclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaBlood2012119112579258922262760
   PubMed Web of Science ®Google Scholar
• RajeNVoglDTHariPNACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM)Blood20131222175923616623
   PubMed Web of Science ®Google Scholar
• InksESJoseyBJJesinkeySRChouCJA novel class of small molecule inhibitors of HDAC6ACS Chem Biol2012733133922047054
   PubMed Web of Science ®Google Scholar
• ShankarSSrivastavaRKHistone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosisAdv Exp Med Biol200861526129818437899
   PubMed Web of Science ®Google Scholar
• LeeJHMahendranbAYaobYDevelopment of a histone deacetylase 6 inhibitor and its biological effectsProc Natl Acad Sci U S A201311039157041570924023063
   PubMed Web of Science ®Google Scholar
• ZhangYKwonSHYamaguchiTMice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normallyMol Cell Biol20082851688170118180281
   PubMed Web of Science ®Google Scholar
• HideshimaTCottiniFOhguchiHRational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myelomaBlood Cancer J20155e31225978432
   PubMed Web of Science ®Google Scholar
• VoglDTRajeNHariPPhase 1B results of ricolinostat (ACY-1215) combination therapy with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (MM)Blood2014124214764
   Web of Science ®Google Scholar
• ButlerKVKalinJBrochierCVistoliGLangleyBKozikowskiAPRational design and simple chemistry yield a superior, neuroprotective hdac6 inhibitor, Tubastatin AJ Am Chem Soc201013231108421084620614936
   PubMed Web of Science ®Google Scholar
• DietzKCCasacciaPHDAC inhibitors and neurodegeneration: at the edge between protection and damagePharmacol Res2010621111720123018
   PubMed Web of Science ®Google Scholar
• RegnaNLReillyaCMIsoform-selective HDAC inhibition in autoimmune diseaseJ Clin Cell Immunol20145207
   Google Scholar
• MarchiniAScottEMRommelaereJOvercoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockadeViruses2016819
   Web of Science ®Google Scholar
• NakashimaHKaufmannJKWangPYHistone deacetylase 6 inhibition enhances oncolytic viral replication in gliomaJ Clin Invest2015125114269428026524593
   PubMed Web of Science ®Google Scholar